May 22 |
Cartesian Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Descartes-08 for the Treatment of Myasthenia Gravis
|
May 13 |
Cartesian Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
|
May 10 |
Cartesian Therapeutics Inc (RNAC) Reports Q1 2024 Earnings: A Detailed Financial and ...
|
May 9 |
Cartesian Therapeutics Reports First Quarter 2024 Earnings
|
May 8 |
Cartesian Therapeutics GAAP EPS of -$10.50, revenue of $5.84M
|
May 8 |
Cartesian Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
|
Apr 22 |
Cartesian Therapeutics to Present at the ASGCT 27th Annual Meeting
|
Apr 10 |
Cartesian Therapeutics' Rare Disease Candidate Shows Long Lasting Benefit Over Argenx's Vyvgart, Analyst Initiates With Buy
|
Apr 4 |
Cartesian Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
|
Mar 28 |
Cartesian Therapeutics Announces Approval of Conversion of Series A Convertible Preferred Stock and Plans to Effect Reverse Stock Split
|